HK1256950A1 - 基因標籤在診斷上評估前列腺癌的治療策略的用途 - Google Patents
基因標籤在診斷上評估前列腺癌的治療策略的用途Info
- Publication number
- HK1256950A1 HK1256950A1 HK18116088.9A HK18116088A HK1256950A1 HK 1256950 A1 HK1256950 A1 HK 1256950A1 HK 18116088 A HK18116088 A HK 18116088A HK 1256950 A1 HK1256950 A1 HK 1256950A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diagnostically
- prostate cancer
- treatment strategies
- genetic signature
- evaluate treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562239181P | 2015-10-08 | 2015-10-08 | |
PCT/CA2016/051180 WO2017059549A1 (en) | 2015-10-08 | 2016-10-07 | Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256950A1 true HK1256950A1 (zh) | 2019-10-04 |
Family
ID=58487193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116088.9A HK1256950A1 (zh) | 2015-10-08 | 2018-12-14 | 基因標籤在診斷上評估前列腺癌的治療策略的用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20180291459A1 (zh) |
EP (1) | EP3359689B1 (zh) |
CN (1) | CN108291262A (zh) |
AU (1) | AU2016334893B2 (zh) |
CA (1) | CA3000865A1 (zh) |
HK (1) | HK1256950A1 (zh) |
WO (1) | WO2017059549A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
EP2291553A4 (en) | 2008-05-28 | 2011-12-14 | Genomedx Biosciences Inc | SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
CA2858581A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
CA2881627A1 (en) | 2012-08-16 | 2014-02-20 | Genomedx Biosciences Inc. | Cancer diagnostics using biomarkers |
US11081225B2 (en) * | 2015-03-30 | 2021-08-03 | The Trustees Of The University Of Pennsylvania | System and method for virtual radiation therapy quality assurance |
EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
US11208697B2 (en) | 2017-01-20 | 2021-12-28 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
WO2018165600A1 (en) | 2017-03-09 | 2018-09-13 | Genomedx Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
WO2018201072A2 (en) | 2017-04-28 | 2018-11-01 | 4D Path Inc. | Apparatus, systems, and methods for rapid cancer detection |
AU2018266733A1 (en) * | 2017-05-12 | 2020-01-16 | Veracyte, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
CN109111522B (zh) | 2017-06-22 | 2022-02-01 | 北海康成(北京)医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
US11299786B2 (en) * | 2018-07-05 | 2022-04-12 | Rutgers, The State University Of New Jersey | Gene panel to predict response to androgen deprivation in prostate cancer |
CN109161597B (zh) * | 2018-11-29 | 2019-03-22 | 上海晟燃生物科技有限公司 | 一种用于前列腺癌早期诊断的外泌体源性基因mRNA标志物组及其应用 |
JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ, インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
CN111041094B (zh) * | 2019-07-11 | 2022-03-08 | 江苏医药职业学院 | 检测tm2结构域蛋白2表达水平的试剂的应用和试剂盒 |
WO2022063957A1 (en) * | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
CA3210515A1 (en) * | 2021-02-01 | 2022-08-04 | The Regents Of The University Of California | Treatment of neuroendocrine cancers |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
US5994069A (en) | 1996-01-24 | 1999-11-30 | Third Wave Technologies, Inc. | Detection of nucleic acids by multiple sequential invasive cleavages |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
US5985557A (en) | 1996-01-24 | 1999-11-16 | Third Wave Technologies, Inc. | Invasive cleavage of nucleic acids |
CN104031984A (zh) * | 2008-02-28 | 2014-09-10 | 俄亥俄州立大学研究基金会 | 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物 |
WO2013116742A1 (en) * | 2012-02-01 | 2013-08-08 | Mayo Foundation For Medical Education And Research | Predicting responses to androgen deprivation therapy and methods for treating prostate cancer |
CA2881627A1 (en) * | 2012-08-16 | 2014-02-20 | Genomedx Biosciences Inc. | Cancer diagnostics using biomarkers |
-
2016
- 2016-10-07 WO PCT/CA2016/051180 patent/WO2017059549A1/en active Application Filing
- 2016-10-07 CA CA3000865A patent/CA3000865A1/en active Pending
- 2016-10-07 AU AU2016334893A patent/AU2016334893B2/en active Active
- 2016-10-07 CN CN201680060699.8A patent/CN108291262A/zh active Pending
- 2016-10-07 US US15/765,711 patent/US20180291459A1/en not_active Abandoned
- 2016-10-07 EP EP16852952.7A patent/EP3359689B1/en active Active
-
2018
- 2018-12-14 HK HK18116088.9A patent/HK1256950A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016334893B2 (en) | 2022-11-17 |
CN108291262A (zh) | 2018-07-17 |
EP3359689A1 (en) | 2018-08-15 |
AU2016334893A1 (en) | 2018-04-19 |
EP3359689A4 (en) | 2019-05-22 |
EP3359689B1 (en) | 2021-04-14 |
US20180291459A1 (en) | 2018-10-11 |
WO2017059549A1 (en) | 2017-04-13 |
CA3000865A1 (en) | 2017-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256950A1 (zh) | 基因標籤在診斷上評估前列腺癌的治療策略的用途 | |
IL288181A (en) | Cancer treatment methods | |
IL259017A (en) | Cancer cure is intended | |
ZA201702382B (en) | Combination therapy for cancer | |
SG11201605585SA (en) | Targeted therapy for small cell lung cancer | |
HK1231381A1 (zh) | 癌症組合療法 | |
SG11201701035SA (en) | Cancer diagnosis and therapy | |
HK1251009B (zh) | 用於治療癌症的治療組合物 | |
IL246761A0 (en) | Combined cancer treatment | |
HK1205254A1 (zh) | 治療癌症的方法 | |
GB201408297D0 (en) | Treatment of cancer | |
GB201409363D0 (en) | Skin cancer treatment | |
IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
GB201407837D0 (en) | Methods of cancer therapy | |
GB201417456D0 (en) | Treatment of cancer | |
HK1200094A1 (zh) | 免疫調節劑用於治療癌症的用途 | |
GB201409362D0 (en) | Treatment of cancer | |
GB201411884D0 (en) | Cancer therapy | |
GB201405449D0 (en) | Treatment of cancer | |
GB201405075D0 (en) | Treatment of cancer | |
GB201417819D0 (en) | Agents for cancer therapy | |
GB201409457D0 (en) | Molecules for cancer therapy | |
GB201406529D0 (en) | Molecules for cancer therapy |